Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial
| Autor: | Saji, Shigehira *, Taira, Naruto, Kitada, Masahiro, Takano, Toshimi, Takada, Masahiro, Ohtake, Tohru, Toyama, Tatsuya, Kikawa, Yuichiro, Hasegawa, Yoshie, Fujisawa, Tomomi, Kashiwaba, Masahiro, Ishida, Takanori, Nakamura, Rikiya, Yamamoto, Yutaka, Toh, Uhi, Iwata, Hiroji, Masuda, Norikazu, Morita, Satoshi, Ohno, Shinji, Toi, Masakazu |
|---|---|
| Zdroj: | In The Lancet Oncology May 2022 23(5):636-649 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|